The practical value of biologics registries in Africa and Middle East: Challenges and opportunities

Clinical Rheumatology

Volumn 31, Issue 3, 2012, Pages 407-416

  Hajjaj Hassouni, Najia ^a,b   Al Badi, Marzooq ^c   Al Heresh, Ala' ^d   Al Emadi, Samar ^e   El Bawendi, Ahmed ^h   El Garf, Ayman ^j   El Hadidi, Khaled ^k   Halabi, Hussein ^l   Hammoudeh, Mohammed ^m   El Hassani, Selma ⁿ   Al Maaini, Mustafa ^g   Nahar, Ibrahim ^o   Ladjouze Rezig, Aïcha ^p   Sellami, Slaheddine ^q   Sweiri, Wafaa ^r   Alswailem, Ramiz ^f   Traub, Beverly ^s   Uthman, Imad ^t   Van Duuren, Elsa ⁱ   Zakraoui, Leith ^u   El Zorkany, Bassel ^k   Carmona, Loreto ^v   Dougados, Maxime ^w   more..

^a MOHAMMED V UNIVERSITY   (Morocco)

^b Hopital El Ayachi   (Morocco)

^c SECURITY FORCES HOSPITAL   (Saudi Arabia)

^d KING HUSSEIN MEDICAL CENTER   (Jordan)

^e WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^f Prince Sultan Military Medical City   (Saudi Arabia)

^g MAFRAQ HOSPITAL   (United Arab Emirates)

^h Tripoli Medical Center   (Libyan Arab Jamahiriya)

ⁱ Jakaranda Hospital   (South Africa)

^j Cairo University   (Egypt)

^k CAIRO UNIVERSITY   (Egypt)

^l KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^m HAMAD MEDICAL CORPORATION   (Qatar)

ⁿ University Cadi Ayyad Faculte de Medecine et de Pharmacie de Marrakech   (Morocco)

^o MUBARAK AL KABEER HOSPITAL   (Kuwait)

^p Ben Aknoun Hospital   (Algeria)

^q Energetique et Photometrie des Sources Tunis   (Tunisia)

^r KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^s American University of Beirut Medical Center ^*  (Germany)

^t AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^u MONGI SLIM HOSPITAL   (Tunisia)

^v CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^w Institut Cochin   (France)

more..

Author keywords

Africa and Middle East; Biologics; Registries; Rheumatoid arthritis; Safety; Tumor necrosis factor inhibitors

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR;

AFRICA; BIOLOGICS REGISTRY; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; HUMAN; INFECTION RISK; INTERMETHOD COMPARISON; LYMPHOMA; META ANALYSIS (TOPIC); MIDDLE EAST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; TUBERCULOSIS; VIRUS INFECTION;

EID: 84859749571     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1918-8     Document Type: Review

References (47)

1. The environment and the middle East. Regional and international cooperation, volume 111. Middle East Institute 2011. Available at http://www.mei.edu/LinkClick.aspx?fileticket=PHoihEEf1CI%3D&tabid=541. Accessed 31 July 2011
2. The Work of WHO in the Eastern Mediterranean Region: annual report of the regional director, 1 January-31 December 2009. Available at http://www.emro.who.int/rd/annualreports/2009/Introduction.htm. Accessed 31 July 2011
3. Maziak W (2006) Health in the Middle East. BMJ 333:815-816
4. Achieving sustainable health development in the African region strategic directions for WHO 2010-2015. World Health Organization regional office for Africa, Brazzaville, 2010. Available at http://www.afro.who.int/index.php? option=com-content&view=article&id=2871:towards-reaching-the-health- related-mdgs&catid=1893&Itemid=2673. Accessed 31 July 2011
5. Symmons D, Mathers C, Pfleger B (2000) The global burden of rheumatoid arthritis in the year 2000. Available at http://www.who.int/healthinfo/ statistics/bod-rheumatoidarthritis.pdf. Accessed 1 August 2011
6. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, van Vollenhoven R, Winthrop KL, Wong J, Zink A, van der Heijde D (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69(6):964-975
7. Scott DL (2009) What have we learnt about the development and progression of early RA from RCTs? Best Pract Res Clin Rheumatol 23:13-24
8. Kvien TK, Heiberg MS, Lie E, Kaufmann C, Mikkelsen K, Nordvåg BY, Rødevand E (2005) A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 23(Suppl 39):S188-S194 (Pubitemid 46657527)
9. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester G, Zink A (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low - results from RABBIT, the German biologics register. Arthritis Res Ther 8:R66
10. Kievit W, Fransen J, Oerlemans AJM, Kuper HH, van der Laar MAFJ, de Rooij DJRAM, De Gendt CMA, Ronday KH, Jansen TL, van Oijen PCM, Brus HLM, Adang EM, van Riel PLCM (2007) The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 66:1473-1478 (Pubitemid 350032655)
11. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP (2009) European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 68(8):1240-1246
12. Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, van Vollenhoven R, Klareskog L, Feltelius N (2009) Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 68(5):648-653
13. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, Lindblad S, Klareskog L (2006) Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 65(6):707-712 (Pubitemid 43799167)
14. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122-2127
15. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837-846
16. Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D (2007) Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 46(8):1345-1354 (Pubitemid 47244512)
17. Karlsson JA, Kristensen LE, Kapetanovic MC, Gülfe A, Saxne T, Geborek P (2008) Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 47(4):507-513
18. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from 8 years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62(1):22-32
19. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, Listing J, Nicola PJ, Tarp U, Zink A, Askling J (2010) EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 69 (9):1596-1602 (Dixon 2010a)
20. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368-2376 (Pubitemid 44204996)
21. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M; BSRBR Control Centre Consortium, Symmons DP; on behalf of the British Society for Rheumatology Biologics Register (2011) The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 50(7):1341-1342
22. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ; British Society for Rheumatology Biologics Register (2007) Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 56(9):2896-2904 (Pubitemid 47502735)
23. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, Pallot-Prades B, Pouplin S, Sacchi A, Chichemanian RM, Bretagne S, Emilie D, Lemann M, Lortholary O, Mariette X, Research Axed on Tolerance of Biotherapies Group (2009) Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 60(7):1884-1894
24. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A; B S R B R Control Centre Consortium, Symmons DP; BSR Biologics Register (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 69(3):522-528
25. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737-744
26. García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernández MV, Gómez-Reino JJ, Carmona L, BIOBADASER 2.0 Study Group (2010) Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 69(10):1751-1755
27. Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, Marchesoni A, Favalli EG, Montecucco C (2010) Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9(3):175-180
28. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections andmalignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275-2285 (Pubitemid 43736578)
29. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D (2011) Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 20(2):119-130
30. Carmona L, Abasolo L, Descalzo MA, Pérez-Zafrilla B, Sellas A, de Abajo F, Gomez-Reino JJ, BIOBADASER Study Group; EMECAR Study Group (2011) Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum 41(1):71-80
31. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP, British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register (2010) Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 62(6):755-763
32. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puéchal X, Wendling D, Lemann M, Ravaud P, Mariette X, RATIO group (2011) Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 70(4):616-623
33. Bernatsky S, Habel Y, Rahme E (2010) Observational studies of infections in rheumatoid arthritis: a metaanalysis of tumor necrosis factor antagonists. J Rheumatol 37(5):928-931
34. Ornbjerg LM, Ostergaard MB, Boyesen M, Thormann P, Tarp A, Bohme U, Dencker WD (2010) Treatment with TNF inhibitors reduces radiographic joint destruction in rheumatoid arthritis patients treated in clinical practice. Arthritis Rheum 62(suppl 10):1841
35. Lie EU, Mikkelsen T, Kalstaa K, Rodevand S, Kaufmann E, Kvien C, Tore K (2010) Better results are achieved by switching directly to biologics than switching via DMARD combinations in RA patients who have failed methotrexate as their initial DMARD: real life data from NOR-DMARD. Arthritis Rheum 62(suppl 10):377
36. Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A (2009) Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68(12):1856-1862
37. Carmona L, Descalzo MA, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ, BIOBADASER and EMECAR Groups (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66(7):880-885 (Pubitemid 46999787)
38. Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results fromthe British Society for Rheumatology Biologics Register. Arthritis Rheum 56(9):2905-2912 (Pubitemid 47502736)
39. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, Geborek P (2007) Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66(5):670-675 (Pubitemid 46707138)
40. Badsha H, Kong KO, Tak PP (2008) Rheumatoid arthritis in the United Arab Emirates. Clin Rheumatol 27(6):739-742
41. Global tuberculosis control. World Health Organization Report 2010. Available at http://www.who.int/tb/publications/global-report/2010/en/index. html. Accessed 3 August 2011
42. World Health Organization, Regional Committee for the Eastern Mediterranean, The growing threats of hepatitis B and C in the Eastern Mediterranean Region: a call for action. Available at http://www.emro.who.int/ rc56/media/pdf/emrc56r5.pdf. Accessed on 10 July 2011
43. Kramvis A, Kew MC (2007) Epidemiology of hepatitis B virus and its genotypes in Africa, and the clinical associations of the genotypes. Hepatol Res 37:S9-S19, Abstract (Pubitemid 47086511)
44. Madhava V, Burgess C, Drucker E (2002) Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2(5):293-302 (Pubitemid 34464740)
45. Coffin CS, Fraser HF, Panaccione R, Ghosh S (2011) Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis 17(1):479-484
46. World Health Organization. Regional Office for the Eastern Mediterranean Region. Cardiovascular diseases. Available at http://www.emro.who.int/ncd/ cardiovascular-diseases.htm. Accessed on 10 July 2011
47. World Health Organization 2011, Media Centre, Cardiovascular Diseases, Fact Sheets. Available at http://www.who.int/mediacentre/factsheets/fs317/en/ index.html. Accessed on 10 July 2011